Sermorelin side effects and risks

Reported side effects

• Injection-site pain, redness or swelling: Historical US label: about 1 in 6; 3/350 stopped because of injection reactions., mild. Rotate injection sites; persistent or spreading redness needs assessment. (source)
• Low thyroid function: Historical pediatric label: 6.5%; this is not an established adult rate., moderate. Check thyroid tests before use and during follow-up. (source)
• Headache, flushing, dizziness or hives: Historical SC label: each <1%. Acute IV flushing also reported; route specific rates differ., mild (source)
• Anti-GHRH antibodies: Continuous infusion trial: 19/20 at 30 mcg/kg/day and 20/20 at 60 mcg/kg/day., moderate. Clinical meaning and relevance to current compounded adult regimens are uncertain. (source)
• Nasal burning, sneezing or runny nose: Most children in an 8 child chronic nasal study reported local reactions; exact counts absent., mild (source)
• Blood sugar increase: Glucose and insulin rose in one pediatric study; the small HIV trial found no significant glucose change., moderate. Monitor glucose, especially with diabetes or glucose-lowering drugs. (source)
• Fluid retention, joint pain or tingling: One FDA blend report described elbow pain. No edema or joint pain occurred in the small HIV trial; adult incidence remains unknown., moderate. Review new swelling, numb hands or joint pain; check for other causes. (source)
• Serious allergic reaction: A 2025 spontaneous report named anaphylactic shock and hospitalization; causation and incidence cannot be established., serious. Stop and get emergency help for breathing trouble or facial swelling. (source)
• Sleep disruption: Forum reports include early waking. A preliminary trial found a small worsening in the average sleep score., moderate (source)

Stop and get help if

• Breathing trouble, throat swelling or widespread hives: Stop and get emergency help now.
• Chest pain, fainting or severe shortness of breath: Get emergency care now.
• New severe headache, vision loss or confusion: Stop and seek urgent medical assessment.
• Fever with spreading redness, pus or worsening pain at an injection site: Get urgent care for possible infection.
• Extreme thirst or urination with vomiting, deep breathing or confusion: Get urgent care for possible severe high blood sugar.
• Persistent or worsening difficulty swallowing: Seek prompt assessment; choking or trouble breathing needs emergency care.

Who should avoid it

• pregnant: No adequate pregnancy safety evidence; the Irish diagnostic label contraindicated pregnancy.
• breastfeeding: Milk transfer and infant effects are unknown; the Irish label contraindicated breastfeeding.
• tryingToConceive: Early-pregnancy and fertility safety are not established. Avoid while trying to conceive.
• under18: Historical pediatric GH-deficiency treatment was a separate specialist indication.
• activeCancer: GH and IGF-I can support cell growth. Avoid in active cancer; this is a GH-axis precaution, not proof sermorelin causes cancer.
• cancerHistory: Review prior cancer and pituitary tumors with the treating specialist; long-term adult sermorelin safety is uncertain.
• other: Known allergy to sermorelin or its excipients was a label contraindication.
• other: Do not add GH stimulation when GH or IGF-I is already abnormally high; evaluate the cause first.
• other: A pituitary or intracranial lesion needs specialist assessment; the historical therapeutic label did not recommend use in this group.
• other: Untreated low thyroid function can alter response; check and address it before use.
• diabetes: GH signaling can change glucose control. Small studies in people without diabetes do not establish safety in diabetes.
• diabeticRetinopathy: A GH-axis precaution based on GH guidance; direct sermorelin safety data in diabetic retinopathy are lacking.
• kidneyDisease: No established adult dose adjustment or safety data. Kidney disease can also complicate interpretation of fluid retention.
• liverDisease: Adult dose adjustment is unknown; liver disease can change IGF-I levels and fluid balance.
• heartCondition: New fluid retention or shortness of breath needs review. The tiny heart-failure registry has no usable outcomes.
• sleepApnea: Review untreated sleep apnea and new snoring; better sleep from sermorelin has not been established.
• seizureDisorder: The historical Irish diagnostic label called for particular caution in epilepsy.
• testedAthlete: WADA prohibits sermorelin at all times under S2.2.4.

Interactions

• Glucocorticoids: Can blunt the GH response. Never stop prescribed steroids to improve a peptide response.
• Somatostatin analogues: These suppress GH release and can reduce the response or change diagnostic test results.
• Insulin and sulfonylureas: GH-axis stimulation can worsen glucose control; diabetes drugs may need review. Direct sermorelin interaction trials are lacking.
• Other GH-releasing drugs: Stacking can amplify GH/IGF-I exposure. Long-term combination benefits and harms are not established.
• Growth hormone or IGF-I: Adds overlapping GH/IGF-I effects and complicates safety monitoring.
• Oral estrogen or anti-estrogens: Oral estrogen or anti-estrogen therapy can change the IGF-I response. This does not justify increasing the peptide dose.
• Anticoagulants: Anticoagulants increase bleeding and bruising risk around injections. No specific sermorelin drug-level interaction is established.
• Drugs affecting diagnostic GH release: These may alter a GHRH test response. A testing clinician should review medicines; do not stop them yourself.

Product quality risks

• FDA documented a recall of a sermorelin/ipamorelin injectable for lack of sterility assurance.
• European seized injectables included sermorelin and products with no active ingredient; this was not a prevalence survey of sermorelin vials.
• Research-use labeling does not establish human drug quality or approval. Compounded drugs also lack FDA premarket approval.